Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy

Journal of Virology

Volumn 70, Issue 6, 1996, Pages 4173-4178

  Gorziglia, Mario I ^a   Kadan, Michael J ^b   Yei, Soonpin ^a   Lim, Jin ^a   Lee, Gai M ^a   Luthra, Rajni ^a   Trapnell, Bruce C ^a,b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; GENE THERAPY; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; VIRUS REPLICATION; DNA REPLICATION; GENE DELETION; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN;

ADENOVIRIDAE; DNA REPLICATION; GENE DELETION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; VIRUS REPLICATION;

EID: 0029664338     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.6.4173-4178.1996     Document Type: Article

References (31)

1. Berkner, K. L. 1988. Development of adenovirus vectors for the expression of heterologous genes. BioTechniques 6:616-624.
2. Brough, D. E., V. Cleghon, and D. F. Klessig. 1992. Construction, characterization, and utilization of cell lines which inducibly express the adenovirus DNA-binding protein. Virology 190:624-634.
3. Engelhardt, J. F., X. Ye, B. Doranz, and J. M. Wilson. 1994. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA 91:61966200.
4. Ensinger, M., and H. Ginsberg. 1972. Selection and preliminary characterization of temperature-sensitive mutants of type 5 adenovirus. J. Virol. 10:328-339.
5. Ginsberg, H. S. 1984. The adenoviruses. Plenum Press, New York.
6. Ginsberg, H. S., M. J. Ensinger, R. S. Kauffman, A. J. Mayer, and U. Ludholm. 1974. Cell transformation: a study of regulation with types 5 and 12 adenovirus temperature-sensitive mutants. Cold Spring Harbor Symp. Quant. Biol. 39:419-426.
7. Graham, F. L., J. Smiley, W. C. Russell, and R. Nairn. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-74.
8. Hitt, M. M., and F. L. Graham. 1990. Adenovirus E1a under the control of heterologous promoters: wide variation in E1a expression levels has little effect on virus replication. Virology 179:667-678.
9. Horwitz, M. S. 1990. Adenoviridae and their replication, p. 1679-1721. In B N. Fields, D. M. Knipe, et al. (ed.), Virology. Raven Press Ltd., New York.
10. Huang, M.-M., and P.Hearing. 1989. Adenovirus early region 4 encodes two gene products with redundant effects in lytic infection. J. Virol. 63:26052615.
11. Jones, N., and T. Shenk. 1979. An adenovirus type 5 early gene function regulates expression of other early viral genes. Proc. Natl. Acad. Sci. USA 76:3665-3669.
12. Kruijer, W., F. M. A. van Schaik, and J. S. Sussenbach. 1981. Structure and organization of the gene coding for the DNA binding protein of adenovirus type 5. Nucleic Acids Res. 9:4439-4457.
13. Lochmuller, H., A. Jani, J. Huard, S. Prescott, M. Simoneau, B. Massie, G. Karpati, and G. Acsadi. 1994. Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (ΔE1 + ΔE3) during multiple passages in 293 cells. Hum. Gene Ther. 5:1485-1491.
14. Mastrangeli, A., C. Danei, M. A. Rosenfeld, L. Stratford-Perricaudet, M. Perricaudet, A. Pavirani, J. P. Lecocq, and R. G. Crystal. 1993. Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer. J. Clin. Invest. 91:225-234.
15. Matsuse, T., S. Hayashi, K. Kuwano, H. Keunecke, W. A. Jefferies, and J. C. Hogg. 1992. Latent adenoviral infection in the pathogenesis of chronic airways obstruction. Am. Rev. Respir. Dis. 146:177-184.
16. Mittereder, N. S. Yei, C. Bachurski, J. Cuppoletti, J. A. Whitsett, P. Tolstoshev, and B. C. Trapnell. 1994. Evaluation of the efficacy and safety of in vivo, adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA. Hum. Gene Ther. 5:719-731.
17. Nolan, G. P., S. Fiering, J.-F. Nicolas, and L. A. Herzenberg. 1988. Fluorescence-activated cell analysis and sorting of viable mammalian cells based on β-D-galactosidase activity after transduction of Escherichia coli lacZ. Proc. Natl. Acad. Sci. USA 85:2603-2607.
18. Rice, S. A., and D. F. Klessig. 1995. Isolation and analysis of the adenovirus type 5 mutants containing deletions in the gene encoding the DNA-binding protein. J. Virol. 56:767-778.
19. Rich, D. P., L. A. Coture, L. M. Cardoza, V. M. Guggio, D. Armentano, P. C. Espino, K. Hehir, M. J. Welsh, A. E. Smith, and R. J. Gregory. 1993. Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Hum. Gene Ther. 4:461-476.
20. Rosenfeld, M. A., W. Siegfried, K. Yoshimura, K. Yoneyainu, M. Fukayama, L. E. Stier, P. K. Paakko, P. Gilardi, L. D. Stratford-Perricaudet, M. Perricaudet, S. Jaliat, A. Pavirani, J. P. Lecocq, and R. G. Crystal. 1991. Adenovirus-mediated transfer of a recombinant α 1-antitrypsin gene to the lung epithelium in vivu. Science 252:431-434.
21. Rosenfeld, M. A., K. Yoshimura, B. C. Trapnell, K. Yoneyama, E. R. Rosenthal, W. Dalemans, M. Fukayama, J. Bargon, L. E. Stier, L. StratfordPerricaudet, M. Perricaudet, B. W. Guggino, A. Pavirani, J.-P. Lecocq, and R. G. Crystal. 1992. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68:143-155.
22. Shenk, T., N. Jones, W. Colby, and D. Fowlkes. 1979. Functional analysis of adenovirus 5 host-range deletion mutants defective for transformation of rat embryo cells. Cold Spring Harbor Symp. Quant. Biol. 44:367-375.
23. Shenk, T., and J. Williams. 1984. Genetic analysis of adenoviruses. Curr. Top. Microbiol. Immunol. 111:1-39.
24. Simon, R. H., J. F. Engelhardt, Y. Yang, M. Zepeda, W. S. Pendleton, M. Grossman, and J. M. Wilson. 1993. Adenovirus-mediated transfer of the CFTR gene to lung of non-human primates: toxicity study. Hum. Gene Ther. 4:771-780.
25. Trapnell, B. C. 1994. Adenoviral vectors for gene transfer. Adv. Drug Delivery Rev. 12:185-199.
26. Trapnell, B. C., and M. Gorziglia. 1994. Gene therapy using adenoviral vectors. Curr. Opin. Biotechnol. 5:617-625.
27. Yang, Y., Q. Li, H. C. Ertl, and J. M. Wilson. 1995. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenovirus. J. Virol. 69:2004-2015.
28. Yang, Y., F. A. Nunes, K. Berencsi, E. E. Furth, E. Gonczol, and J. M. Wilson. 1994. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91:4407-4411.
29. Yang, Y., F. A. Nunes, K. Berencsi, E. Gonczol, J. F. Engelhardt, and J. M. Wilson. 1994. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy for cystic fibrosis. Nat. Genet. 7:362-369.
30. Yei, S., N. Mittereder, K. Tang, C. O'Sullivan, and B. C. Trapnell. 1994. Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther. 1: 192-200.
31. Yei, S., N. Mittereder, S. Wert, J. A. Whitsett, R. W. Wilmott, and B. C. Trapnell. 1994. In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum. Gene Ther. 5:731-744.